L
Laurent Machet
Researcher at François Rabelais University
Publications - 285
Citations - 6871
Laurent Machet is an academic researcher from François Rabelais University. The author has contributed to research in topics: Melanoma & Lymphoma. The author has an hindex of 36, co-authored 273 publications receiving 5824 citations. Previous affiliations of Laurent Machet include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Pascal Joly,Maud Maho-Vaillant,Catherine Prost-Squarcioni,Vivien Hébert,Estelle Houivet,Sébastien Calbo,Frédérique Caillot,Marie-Laure Golinski,Bruno Labeille,Catherine Picard-Dahan,Carle Paul,Marie-Aleth Richard,Jean-David Bouaziz,Sophie Duvert-Lehembre,Philippe Bernard,Frédéric Caux,Marina Alexandre,Saskia Ingen-Housz-Oro,Pierre Vabres,Emmanuel Delaporte,Gaëlle Quéreux,Alain Dupuy,Sébastien Debarbieux,Martine Avenel-Audran,Michel D'Incan,Christophe Bedane,Nathalie Beneton,Denis Jullien,Nicolas Dupin,Laurent Misery,Laurent Machet,Marie Beylot-Barry,Olivier Dereure,Bruno Sassolas,Thomas Vermeulin,Jacques Benichou,P. Musette +36 more
TL;DR: Data from this trial suggest that first-line use of rituximab plus short-termprednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events.
Journal ArticleDOI
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
Tony Petrella,Martine Bagot,Rein Willemze,Marie Beylot-Barry,Béatrice Vergier,Michèle Delaunay,Chris J.L.M. Meijer,Philippe Courville,Pascal Joly,Florent Grange,Anne de Muret,Laurent Machet,Anne Dompmartin,Jacques Bosq,Anne Durlach,Philippe Bernard,Sophie Dalac,Pierre Dechelotte,Michel D'Incan,Janine Wechsler,Michael A. Teitell +20 more
TL;DR: The major clinical, histopathologic, and phenotypic aspects of the disease and diagnostic criteria and data suggesting a plasmacytoid dendritic cell origin for the tumor cells are provided.
Journal ArticleDOI
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Clinicopathologic Features and Prognostic Analysis in 60 Cases
Florent Grange,Marie Beylot-Barry,Phillipe Courville,Eve Maubec,Martine Bagot,Béatrice Vergier,Pierre Souteyrand,Laurent Machet,Sophie Dalac,Eric Estève,Isabelle Templier,Emmanuel Delaporte,Marie-Françoise Avril,Caroline Robert,Stéphane Dalle,Liliane Laroche,Michèle Delaunay,Pascal Joly,Janine Wechsler,Tony Petrella +19 more
TL;DR: Primary cutaneous diffuse large B-cell lymphoma, leg type is a distinct entity with a poor prognosis, particularly in patients with multiple tumors on the legs, but the prognosis could be improved with combinations of anthracycline-containing chemotherapies and rituximab.
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alex Menzies,Thierry Lesimple,Michele Maio,Gerald P. Linette,Michael C. Brown,Peter Hersey,Inge Marie Svane,Laurent Mortier,Jacob Schachter,Catherine Barrow,Ragini R. Kudchadkar,Xinni Song,Caroline Dutriaux,Pietro Quaglino,Friedegund Meier,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Bernard Guillot,Claus Garbe,Pablo Luis Ortiz Romero,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Jean-Philippe Arnault,Philippe Saiag,Carmen Loquai,Frank Meiss,Jan-Christoph Simon,Gil Bar-Sela,Vanna Chiarion Sileni,Bernard Fitzharris,Mike McCrystal,Phillip Parente,Jean-Francois Baurain,Patrick Combemale,Céleste Lebbé,Axel Hauschild,Naoya Yamazaki,Reinhard Dummer,Mohammed M. Milhem,Marcin Dzienis,John Walker,Lionel Geoffrois,Marie-Thérèse Leccia,Lutz Kretschmer,Daniel Hendler,Michal Lotem,Andrzej Mackiewicz,Lidija Sekulovic,Elaine Dunwoodie,Christoph Hoeller,Laurent Machet,Jessica C. Hassel,Geke A. P. Hospers,Maria-Jose Passos,Max Levin,Martin Fehr,Philippa Corrie,Ashita Waterston,Sigrun Hallmeyer,Henrik Schmidt,Vincent Descamps,Jean-Philippe Lacour,Carola Berking,Felix Kiecker,Pier Francesco Ferrucci,Kenji Yokota,Maureen J.B. Aarts,Michael B. Jameson,Anna Katharina Winge-Main,Paula Ferreira,Kevin B. Kim,Catriona M. McNeil,Reiner Hofmann-Wellenhof,Joseph Kerger,François Aubin,Jochen Utikal,Virginia Ferraresi,Takashi Inozume,Yoshio Kiyohara,Gerard Groenewegen,Helena Kapiteijn,Suzana Matkovic,Wolf-Henning Boehncke,Richard Casasola,Timothy Crook,Ernest Marshall,Tanja Skytta,Marie-Francoise Avril,Thomas Jouary,Rüdiger Hein,Patrick Terheyden,Jun Aoi,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina,Paul C. Nathan +131 more
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.
Journal ArticleDOI
Delays in diagnosis and melanoma prognosis (I): the role of patients.
Marie Aleth Richard,Jean J. Grob,M. F. Avril,Michèle Delaunay,Johany Gouvernet,Pierre Wolkenstein,Pierre Souteyrand,Brigitte Dréno,Jean Jacques Bonerandi,Sophie Dalac,Laurent Machet,Jean Claude Guillaume,Jacqueline Chevrant-Breton,Catherine Vilmer,François Aubin,Bernard Guillot,Marie Beylot-Barry,Catherine Lok,Nadia Raison-Peyron,Philippe Chemaly +19 more
TL;DR: Individuals with a high number of atypical nevi, those who were aware to be at risk, and those who regularly visited a dermatologist tended to detect their melanoma more rapidly.